文献速递先天性心脏病外科瓣膜外科

经导管肺动脉瓣置换:新型聚碳酸酯聚氨酯瓣膜

Transcatheter pulmonary valve replacement: a new polycarbonate urethane valve.
PubMed 文献 · Eur J Cardiothorac Surg · 2021-01-01

本研究在6只羊中评估了一种新型 dip-coated 低剖面三叶聚碳酸酯聚氨酯(PCU)瓣膜,该瓣膜安装在自膨胀镍钛合金支架上。经股静脉途径经皮植入,分为1个月和6个月随访组。所有动物均实现原位定位,除1例外瓣膜功能良好,跨瓣峰值压差1个月为4.6 ± 1.0 mmHg,6个月为4.4 ± 2.3 mmHg,未见支架断裂、瓣叶钙化或血栓形成。

要点

  • 新型PCU瓣膜经导管植入羊肺动脉瓣位置成功,短期随访血流动力学良好。
  • 6个月观察期内未见支架断裂、瓣叶钙化或血栓形成,组织相容性良好。
  • 该技术可能为宽大、顺应性好的右心室流出道疾病提供自膨胀瓣膜治疗选项。

核心结论

  • 经导管肺动脉瓣置换使用新型 dip-coated 镍钛合金带瓣支架在羊模型中成功实施。
  • 三叶PCU瓣膜在6个月观察期内表现出良好的功能和组织相容性。

研究设计与样本

  • 实验性羊研究,共6只连续羊分为2组,3只随访1个月,3只随访6个月。
  • 瓣膜通过 dip-coating 技术制成,安装在锥形自膨胀镍钛合金支架上,瓣叶厚度100-150 µm。
  • 经股动脉途径经皮植入,术前、术后及随访终点行血管造影和经胸超声心动图检查。

主要发现

  • 所有动物均实现瓣膜原位定位。
  • 除1例外,随访期间所有瓣膜功能良好。
  • 跨PCU带瓣支架的峰值压差1个月为4.6 ± 1.0 mmHg,6个月为4.4 ± 2.3 mmHg。
  • 宏观和微观死后评估显示良好的形态学和结构结果。
  • 未见支架断裂、瓣叶钙化或血栓形成。

关键数值与推荐

  • 瓣叶厚度为100-150 µm。
  • 跨瓣峰值压差1个月为4.6 ± 1.0 mmHg,6个月为4.4 ± 2.3 mmHg。

临床怎么用

  • 对于右心室流出道宽大、顺应性好的患者,自膨胀带瓣支架可能提供经导管肺动脉瓣置换的新选择。
  • 新型PCU瓣膜短期随访血流动力学和组织相容性良好,但需进一步临床研究验证。

局限性

  • 样本量小(6只羊),随访时间短(最长6个月)。
  • 为动物实验研究,结果不能直接外推至人类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Transcatheter pulmonary valve replacement has become a valid treatment option for right ventricular outflow tract diseases. However, some limitations occur in patients with wide, compliant right ventricular outflow tracts that might be amenable to treatment with self-expanding valved protheses. An experimental ovine study was designed to evaluate a novel dip-coated, low-profile trileaflet polycarbonate urethane (PCU) heart valve mounted into a self-expandable nitinol stent. METHODS: The PCU valves were produced by a dip-coating technique, mounted in a conical-shaped nitinol stent and provided with a leaflet thickness of 100-150 µm. The valved stents were implanted percutaneously via transfemoral access in 6 consecutive sheep divided into 2 groups. Three animals were followed up for 1 month and the remainder, for 6 months. Angiographic measurements and transthoracic echocardiography were performed before and after implantation and at the end of the 1- or 6-month observation period, respectively. RESULTS: Orthotopic positioning of the valve was achieved in all animals. All except 1 had competent valves during the follow-up period. The peak-to-peak gradient across the PCU valved stents was 4.6 ± 1.0 mmHg after 1 month and 4.4 ± 2.3 mmHg after 6 months of follow-up. Macroscopic and microscopic post-mortem evaluation indicated good morphological and structural results. There were no stent fractures, leaflet calcification or thrombus formation. CONCLUSIONS: This study demonstrates successful transcatheter pulmonary valve replacement with a novel dip-coated valved nitinol stent. The trileaflet PCU prostheses indicated good functional and biocompatible properties after a 6-month observation period.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Lutter G, Topal A, Hansen JH, et al. Transcatheter pulmonary valve replacement: a new polycarbonate urethane valve. Eur J Cardiothorac Surg. 2021. PMID: 33538794. doi:10.1093/ejcts/ezaa479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。